Denosumab Injection (Xgeva) and Foscarnet Intravenous
Determining the interaction of Denosumab Injection (Xgeva) and Foscarnet Intravenous and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with other drugs that can reduce serum calcium may potentiate the risk of hypocalcemia associated with foscarnet. Foscarnet chelates with divalent metal ions and causes a dose-related reduction in ionized serum calcium. Hypocalcemia may occur in 15% to 30% of treated patients. Severe hypocalcemia (Trousseau's and Chvostek's signs) and fatalities have been reported rarely in postmarketing surveillance during use of foscarnet in combination with intravenous pentamidine. The interaction has not been reported with other drugs. MANAGEMENT: Close monitoring is recommended during concomitant use of foscarnet with other drugs that are known to affect calcium concentrations. Serum creatinine and electrolyte levels should be assessed prior to initiating therapy and frequently during therapy. Patients should be advised to promptly notify their physician if they experience potential symptoms of hypocalcemia such as perioral tingling, numbness in extremities, and paresthesias. References "Product Information. Foscavir (foscarnet)." Astra USA, Westborough, MA. Youle M, Clarbour J, Gazzard B, Chanas A "Severe hypocalcemia in AIDS patients treated with foscarnet and pentamidine." Lancet 1 (1988): 1455-6 "Foscarnet: a review." Drugs 41 (1991): 106-29
Professional:MONITOR: Coadministration with other drugs that can reduce serum calcium may potentiate the risk of hypocalcemia associated with foscarnet. Foscarnet chelates with divalent metal ions and causes a dose-related reduction in ionized serum calcium. Hypocalcemia may occur in 15% to 30% of treated patients. Severe hypocalcemia (Trousseau's and Chvostek's signs) and fatalities have been reported rarely in postmarketing surveillance during use of foscarnet in combination with intravenous pentamidine. The interaction has not been reported with other drugs.
MANAGEMENT: Close monitoring is recommended during concomitant use of foscarnet with other drugs that are known to affect calcium concentrations. Serum creatinine and electrolyte levels should be assessed prior to initiating therapy and frequently during therapy. Patients should be advised to promptly notify their physician if they experience potential symptoms of hypocalcemia such as perioral tingling, numbness in extremities, and paresthesias.
- "Product Information. Foscavir (foscarnet)." Astra USA, Westborough, MA.
- Youle M, Clarbour J, Gazzard B, Chanas A "Severe hypocalcemia in AIDS patients treated with foscarnet and pentamidine." Lancet 1 (1988): 1455-6
- "Foscarnet: a review." Drugs 41 (1991): 106-29
Generic Name: denosumab
Brand name: Prolia, Xgeva
Synonyms: Denosumab
Generic Name: foscarnet
Brand name: Foscavir
Synonyms: Foscarnet
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Denosumab Injection (Xgeva)-Foscarnet Sodium
- Denosumab Injection (Xgeva)-Foscavir
- Denosumab Injection (Xgeva)-Fosfomycin
- Denosumab Injection (Xgeva)-Fosfomycin Tromethamine
- Denosumab Injection (Xgeva)-Fosinopril
- Denosumab Injection (Xgeva)-Fosinopril and Hydrochlorothiazide
- Foscarnet Intravenous-Denosumab Subcutaneous
- Foscarnet Intravenous-Denovo
- Foscarnet Intravenous-Dent-O-Kain/20
- Foscarnet Intravenous-Denti-Care Denti-Freeze Topical Anesthetic
- Foscarnet Intravenous-DentiPatch
- Foscarnet Intravenous-Deoxycholic acid